Hepion Financial Statements From 2010 to 2024

HEPA Stock  USD 0.64  0.03  4.48%   
Hepion Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Hepion Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Hepion Pharmaceuticals financial statements helps investors assess Hepion Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Hepion Pharmaceuticals' valuation are summarized below:
Market Capitalization
4.5 M
Earnings Share
(4.40)
We have found one hundred twenty available fundamental trends for Hepion Pharmaceuticals, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of Hepion Pharmaceuticals regular market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 20.9 M, whereas Enterprise Value is forecasted to decline to (2.1 M).
Check Hepion Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Hepion Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 81.3 K, Selling General Administrative of 6.5 M or Other Operating Expenses of 50.9 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.86. Hepion financial statements analysis is a perfect complement when working with Hepion Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Hepion Pharmaceuticals Correlation against competitors.
For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.

Hepion Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets27.5 M18.1 M21.9 M
Slightly volatile
Other Current Liabilities1.8 M2.7 M1.4 M
Slightly volatile
Total Current Liabilities3.8 M5.3 M3.1 M
Slightly volatile
Accounts PayableM2.3 M1.5 M
Slightly volatile
Cash22.3 M14.8 M17.7 M
Slightly volatile
Cash And Short Term Investments24.2 M14.8 M17.9 M
Slightly volatile
Common Stock Total Equity9.2 K8.8 K3.9 K
Slightly volatile
Common Stock Shares Outstanding4.2 MM1.1 M
Slightly volatile
Liabilities And Stockholders Equity27.5 M18.1 M21.9 M
Slightly volatile
Non Current Liabilities TotalM5.5 M3.2 M
Slightly volatile
Total Liabilities7.7 M10.8 M6.2 M
Slightly volatile
Total Current Assets24 M17.5 M19.1 M
Slightly volatile
Common Stock4584822.6 K
Pretty Stable
Non Currrent Assets Other228.6 K364.2 K168.5 K
Slightly volatile
Property Plant And Equipment Gross652.9 K621.8 K247.3 K
Slightly volatile
Property Plant And Equipment Net289.1 K242.4 K198.3 K
Slightly volatile
Non Current Assets Total576.2 K606.6 K2.6 M
Slightly volatile
Other Assets465.6 K490.1 K1.3 M
Pretty Stable
Capital Surpluse270.4 M257.5 M103.3 M
Slightly volatile
Other Current AssetsM2.7 M1.4 M
Slightly volatile
Property Plant Equipment89.2 K93.9 K192.4 K
Slightly volatile
Short and Long Term Debt Total360 K209 K363.5 K
Slightly volatile
Other Liabilities3.2 M2.3 M4.7 M
Slightly volatile
Deferred Long Term Liabilities349.7 K368.1 K2.4 M
Slightly volatile
Non Current Liabilities OtherM1.6 M2.7 M
Slightly volatile
Intangible Assets2.6 M2.9 M3.1 M
Slightly volatile
Net Invested Capital5.3 M5.6 M17.5 M
Slightly volatile
Net Working Capital11.6 M12.2 M19 M
Slightly volatile
Short Term Debt359.9 K231.8 K334.1 K
Slightly volatile
Short and Long Term Debt1.2 M1.3 M1.4 M
Slightly volatile
Capital Stock1.4 M1.7 M1.7 M
Slightly volatile
Long Term Debt141.3 K158.9 K173.1 K
Slightly volatile
Long Term Debt Total141.3 K158.9 K173.1 K
Slightly volatile
Preferred Stock Total Equity1.4 M1.5 M1.7 M
Slightly volatile
Current Deferred Revenue2.6 M2.4 M2.7 M
Slightly volatile

Hepion Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization81.3 K67.1 K198.9 K
Slightly volatile
Selling General Administrative6.5 M9.6 M5.2 M
Slightly volatile
Other Operating Expenses50.9 M48.4 M18.5 M
Slightly volatile
Research Development37.4 M35.6 M12.6 M
Slightly volatile
Total Operating Expenses50.9 M48.4 M18.5 M
Slightly volatile
Interest Income150.4 K158.3 K2.3 M
Slightly volatile
Reconciled Depreciation54.2 K73.3 K39.1 K
Slightly volatile
Cost Of Revenue64.2 K67.1 K39.8 K
Slightly volatile
Preferred Stock And Other Adjustments3.8 M3.6 M915.3 K
Slightly volatile
Non Recurring1.5 M1.7 M1.8 M
Slightly volatile
Selling And Marketing Expenses53.7 K60.4 K65.8 K
Slightly volatile

Hepion Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow22.4 M14.8 M17.8 M
Slightly volatile
Begin Period Cash Flow53.7 M51.2 M18.3 M
Slightly volatile
Depreciation37.9 K67.1 K28.1 K
Slightly volatile
Stock Based Compensation1.8 M1.3 M1.2 M
Slightly volatile
Dividends Paid95010004.1 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables2.6 M2.5 M1.3 M
Slightly volatile
Capex To Depreciation0.20.21314.1631
Slightly volatile
Payables Turnover0.01880.02860.0193
Slightly volatile
Cash Per Share3.543.7236729
Slightly volatile
Days Payables Outstanding12.1 K12.8 K26.5 K
Slightly volatile
Income Quality0.660.83570.7218
Slightly volatile
Intangibles To Total Assets0.05780.06090.2631
Slightly volatile
Net Debt To EBITDA0.280.29590.9647
Very volatile
Current Ratio3.823.30584.1217
Slightly volatile
Graham Number21.4222.54614.1 K
Slightly volatile
Capex Per Share0.00340.00367.0056
Slightly volatile
Interest Debt Per Share0.030.031678.6355
Slightly volatile
Debt To Assets0.00610.00640.3043
Slightly volatile
Days Of Payables Outstanding12.1 K12.8 K26.5 K
Slightly volatile
Ebt Per Ebit1.241.01831.1166
Pretty Stable
Long Term Debt To Capitalization0.00350.00390.0043
Slightly volatile
Quick Ratio3.823.30584.1217
Slightly volatile
Net Income Per E B T0.740.99170.8958
Pretty Stable
Cash Ratio3.582.7953.8662
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.00031.012
Slightly volatile
Debt Ratio0.00610.00640.3043
Slightly volatile

Hepion Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap20.9 M11.6 M25.6 M
Very volatile

Hepion Fundamental Market Drivers

Cash And Short Term Investments14.8 M

Hepion Upcoming Events

19th of February 2024
Upcoming Quarterly Report
View
10th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
19th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Hepion Pharmaceuticals Financial Statements

Hepion Pharmaceuticals stakeholders use historical fundamental indicators, such as Hepion Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Hepion Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Hepion Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Hepion Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Hepion Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2.4 M2.6 M
Cost Of Revenue67.1 K64.2 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Hepion Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hepion Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hepion Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hepion Pharmaceuticals Stock:
Check out the analysis of Hepion Pharmaceuticals Correlation against competitors.
For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hepion Pharmaceuticals. If investors know Hepion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hepion Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.40)
Return On Assets
(0.93)
Return On Equity
(1.90)
The market value of Hepion Pharmaceuticals is measured differently than its book value, which is the value of Hepion that is recorded on the company's balance sheet. Investors also form their own opinion of Hepion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Hepion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hepion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Hepion Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hepion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hepion Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hepion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.